MSLN and Miyoshi myopathy: The results of our previous study investigating SMRP as a tumour biomarker for MM, showed significantly higher SMRP levels before treatment than the levels in complete response, partial response, and a borderline significant difference between levels before treatment and stable disease.12 These findings suggest SMRP not only as a superior diagnostic biomarker for MM compared with fibulin-3 as presented in the study of Creaney et al. 26, but also as a superior biomarker for evaluating tumour response to treatment.